Compare SFNC & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFNC | VERA |
|---|---|---|
| Founded | 1903 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 1998 | 2021 |
| Metric | SFNC | VERA |
|---|---|---|
| Price | $21.26 | $42.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $22.83 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 987.6K | 836.9K |
| Earning Date | 04-21-2026 | 05-27-2026 |
| Dividend Yield | ★ 4.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.13 | N/A |
| Revenue Next Year | $8.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.00 | $18.53 |
| 52 Week High | $22.33 | $56.05 |
| Indicator | SFNC | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 56.77 | 45.32 |
| Support Level | $18.48 | $40.87 |
| Resistance Level | $21.53 | $56.05 |
| Average True Range (ATR) | 0.60 | 1.98 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 56.90 | 43.60 |
Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.